Mitapivat in stable sickle cell disease

Phase 1, open-label trial of mitapivat in sickle cell disease (SCD), sponsored by National Institutes of Health. Primary endpoints: Number of Participants With Most Common Reported Drug Related Adverse Events at 14 weeks and Number of Participants With Serious Adverse Events That Were Possibly Drug-related at 14 weeks. Started Jul 2019; status: completed.